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Beta-blockers and the thyrotoxic patient for thyroid and 
non-thyroid surgery: a clinical reviewTay S1*, Khoo E1, Tancharoen C2, Lee I3
Abstract
IntroductionThyrotoxic patients presenting for surgery should ideally be biochemi-cally and clinically euthyroid. This is conventionally achieved through the use of anti-thyroid drugs, beta-block-er therapy and iodine. However, there are some circumstances where anti-thyroid drugs may not be a viable op-tion. The implications of this scenario are not widely reported in the litera-ture. This clinical review looks at the evidence on the safety of beta-block-er therapy without the use of anti-thyroid drugs in the preparation of the thyrotoxic patient for surgery. We also highlight key points in the patho-physiology of thyrotoxicosis and the management goals of these patients.
ConclusionIn circumstances where the use of anti-thyroid drugs is not possible in the preoperative management of patients for thyroid or non-thyroid surgery, the use of beta-blockers has been shown to be safe and effective. Safety can be increased by using iodine with or without corticoster-oids up to the day of surgery in the rapid preoperative preparation of a  severely thyrotoxic patient.
IntroductionA thyrotoxic patient undergoing sur-gery should ideally be rendered bio-chemically and clinically euthyroid 
prior to surgery1. This is through a combination of anti-thyroid drugs (ATD) and beta-blockers. However, in some circumstances, patients can be adequately managed with beta-blockers and potassium iodide1. The question remains though, how safe is this therapy compared with the conventional use of ATDs and beta-blockers? There have been several studies in the past that have suggest-ed a role for sole beta-blocker ther-apy in the preoperative management of thyrotoxic patients. This paper aims to review the current literature to evaluate the safety of this practice.
DiscussionThyrotoxicosis is a hypermetabolic syndrome secondary to elevated lev-els of thyroid hormones. The most common causes of thyrotoxicosis are Graves’ disease, toxic multinodular goitre and toxic adenoma1,2. These diseases cause hyperthyroidism or an increase in both the synthesis and secretion of thyroid hormones by the thyroid. Other causes of thyrotoxico-sis include thyroiditis or iatrogen-esis. These causes do not increase the synthesis of thyroid hormones, 
and the use of ATDs is therefore  contraindicated.The symptoms of thyrotoxicosis are due to an excess of beta-adrener-gic activity, and include hyperactivity, nervousness, tremor, weight loss and sweating3–6. Relevant to anaesthe-sia, an excess of thyroid hormones can affect cardiovascular physiology as shown in Figure 1. Importantly, these cardiovascular effects predis-pose a patient to develop supraven-tricular arrhythmias. In patients with pre-existing cardiac disease, ischae-mia or failure may be precipitated7. Thyroid storm is a life-threatening complication of uncontrolled and severe thyrotoxicosis that can be triggered by various insults such as surgery, anaesthesia, manipulation of the thyroid or sepsis. It carries a high mortality rate of 10%–30%8,9. Its incidence, however, is rare due to the widespread use of ATDs and  beta-blockers1–6,9.Patients presenting for surgery with thyrotoxicosis can be divided into those requiring emergent care unrelated to thyroid, or those that are thyroid-related. The indica-tions for thyroid-related surgery are 
* Corresponding author Email: STANLEY.TAY@nt.gov.au1  Department of Anaesthesia, Royal Darwin Hospital, Darwin, Australia.2  Department of Medicine, St. Vincent’s Hospital, Melbourne, Australia.3  Wellbeing & Preventable Chronic Diseases Department, Menzies School of Health Research, Darwin, Australia. Figure 1: Effect of thyroid hormones on cardiovascular physiology (Adapted from Klein et al. 2001)7.
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are not available in many countries1. Use of iodine should be restricted in the preoperative period for no longer than 10 days. This is because of an “escape phenomenon” where an excess of iodine incorporates into new thyroid hormones, leading to a secondary rise in thyroid hormones and worsening of the thyrotoxic state. This occurs after 10–14 days of  therapy15,21,22.Several clinical features of thyro-toxicosis are due to sympathetic-mediated stimulation relating to increased beta-adrenoreceptor up-regulation and sensitization to cat-echolamines3,15,23. Since the 1960s, propranolol has been the agent of choice to attenuate the heightened beta-adrenoreceptor-mediated ef-fects of thyrotoxicosis2,24,25. Other beta-blockers have become available since then, including more beta-1 selective agents (metoprolol), long-acting agents (atenolol) and very short-acting agents (esmolol). Each has their own advantages and dis-advantages in managing a thyrotoxic patient. However, the main limita-tion with all beta-blockers is that they do not alter the underlying hy-permetabolic state. Therefore, long-term sole beta-blocker therapy is not  recommended15,26.
Rare side effects include agranulocy-tosis and hepatotoxicity1,5,17.  Common side effects include fever, arthralgia, rash and urticaria 1,5,17. Since ATDs have no effect on the release of pre-formed thyroid hormones, it takes several weeks of therapy to render a patient euthryoid5,16,17. This regimen, however, has been reported to result in a larger, more vascular and friable gland due to thyrotropin (TSH) stim-ulation of the thyroid in response to ATD-induced hypothyroidism15,13. This unwanted effect can be less-ened by increasing the duration of treatment13,18 or through the use of iodine1.In supra-physiological doses, Lu-gol’s iodine inhibits thyroid hormone synthesis via the Wolff–Chaikov ef-fect, and the release of preformed hormones3,15. The anti-thyroid ef-
fects are seen within the first 24 hours and maximally at 10 days of therapy15,19. Iodine has also been re-ported to reduce vascularity and fri-ability of the thyroid gland, thereby possibly lowering surgical bleeding risk19,20. Oral iodinated radiographic contrast agents such as ipodate and iopanoic acid can also be used. It has 
the additional beneficial effect of re-ducing peripheral conversion of T4 to T315. Unfortunately, these agents 
 summarized in Table 11,10. There are currently three major forms of treat-ment: medical therapy (ATD),131 I and surgery1,11. All are safe and equally as successful when comparing long-term quality of life12, but each with their own advantages and disadvan-tages. Choice of treatment must take into account numerous factors—pa-tient age, sex, desire to have children, underlying comorbidities and the personal “philosophies” of both the patient and physician or surgeon13.
Current preoperative preparation 
of a thyrotoxic patientPreoperative optimization of the thyrotoxic patient depends on its aetiology. Targets for action are pathways in thyroid hormone syn-thesis, secretion and its peripheral action1,14,15. The aim is to reduce the risk of perioperative thyroid storm. For thyrotoxic patients secondary to hyperthyroidism (not thyroiditis or iatrogenesis), elective surgery should be postponed for 3–6 weeks so that a euthyroid state can be achieved with an ATD and beta-blockers as indicated for symptomatic relief and cardioprotection1,2,16. With emergent 
surgery, there is insufficient time to allow ATDs to achieve euthyroid state. Therefore, a combination of beta-blockers, iodine and high-dose steroids is given to rapidly facilitate safe surgery.Thionamides are a class of ATD that include propylthiouracil (PTU), carbimazole and its active metabo-lite methimazole15. They act by halt-ing thyroid hormone synthesis by 
blocking organification of iodine and  coupling of iodotyrosines. PTU additionally inhibits peripheral dei-odination of thyroxine (T4) to trii-odotyrosine (T3)6,15. Carbimazole or methimazole, however, are generally 
preferred as they have the benefit of once-a-day administration and re-duced side effects compared to PTU1. 
The exception is during the first tri-mester of pregnancy where PTU is not considered to be teratogenic1. 
Table 1 Indications for thyroid-related surgery
Rapid correction of thyrotoxic state
Failure, adverse side effects or non-compliance of medical therapy
Avoidance of exposure to radioactivity to 131I (children or pregnant/breast-feed-
ing women)
Large goitre (>80 g)
Children <5 year of age
Moderate to severe or sight threatening Graves’ ophthalmopathy
Presence of symptoms or signs of compression within the neck 
Substernal or retrosternal extension of thyroid
Potential for coexisting thyroid cancer
Coexisting hyperparathyroidism
Thyroid-stimulating hormone producing pituitary tumours
Patient preference
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 supervision is required, especially in 
the first 24 hours post-surgery. Also, instead of weaning beta-blockers immediately after surgery like one would do if a patient were conven-tionally prepared with ATDs, they should be continued for 5–7 days post-operatively to prevent hyper-thyroid symptoms and avert the risk of thyroid storm. This is because the biological half-lives of the excess cir-culating T3 is 1–2 days and T4 is 3–4 days in hyperthyroidism46.There have been several small ret-rospective case series which have reported the occurrence of thyroid crisis in patients undergoing surgery following sole preparation with pro-pranolol24,45,47–50. This is in contrast to the prospective studies shown in Table 2. The circumstances in which thyroid storm occurred were either the dosage of propranolol being too low (160 mg/day or less) or the re-sponse to beta-blocker therapy not 
iodine in the preoperative  treatment and stabilization of the thyrotoxic pa-tient. These results are summarized in Table 231–45. They show that this re-gime can safely provide rapid control of the peripheral manifestations of hyperthyroidism, producing a clini-cally euthyroid patient in a relatively short period of time.Given that beta-blockers do not interfere with the release of thyroid hormone, the fear remains that a clin-ically euthyroid patient treated with beta-blockers only remains exposed to high levels of circulating thyroid hormone. This then increases the risk of perioperative thyroid storm. It has been reported that the incidence of post-operative hyperthyroid symp-toms occurs in 5%–20% of patients prepared with beta-blocker therapy alone13,40–44. Many of these cases may be attributed to the short half-life of propranolol and the need for regu-lar administration. Therefore, close 
Finally, high doses of dexametha-sone, hydrocortisone or betametha-sone are used as adjunct therapy when a severely thyrotoxic patient needs to be rapidly prepared for surgery27. They inhibit secretion of thyroid hormone and peripheral  conversion of T4 to T33,17,28.
Safety of beta-blockers as sole 
therapyThe use of ATDs may not be possible in patients undergoing emergency surgery, non-compliant patients and patients that are refractory to ATDs16,29,30. In view of the established safety of conventionally prepared thyrotoxic patients for surgery, it is essential that any deviation from this is comparably safe and effective31.During the 1970s to the mid-1990s, numerous studies were performed with results advocating the use of beta-blockers, in particular propran-olol, alone or in combination with 
Table 2 Six hundred and eighty thyrotoxic patients for thyroidectomy prepared with beta-blockers ± iodine only  
(Adapted from Lee et al. 1982)21
Author Year
No. of 
patients
Beta-blocker Iodine Surgery Storm Results Country
Lee et al.32 1973 20 Propanolol No Yes No Good USA
Michie et al.33 1974 37 Propanolol No Yes No Good Scotland
Michie34 1975 47 Propanolol No Yes No Good England
Toft et al.35 1976 40 Propanolol No Yes No Good Scotland
Caswell et al.36 1978 24 Propanolol No Yes No Good USA
Anderberg et al.37 1979 38 Propanolol No Yes No Good Sweden
Tevaarwerk et al.38 1979 20 Propanolol No Yes No Good Canada
Malliere et al.39 1980 5 Propanolol No Yes No Good France
Feek et al.22 1980 10 Propanolol Yes Yes No Good Scotland
Feely et al.40 1981 44 Propanolol No Yes No Good England
Lee et al.21 1982 140 Propanolol No Yes No Good France
Peden et al.41 1982 17 Nadolol Yes Yes No Good Scotland
Lennquist et al.42 1985 93 Propanolol No Yes No Good Sweden
Gerst et al.26 1986 12 Atenolol/Nadolol No Yes No Good USA
Adlerberth et al.43 1987 15 Metoprolol No Yes No Good Sweden
Vickers et al44 1990 95 Propanolol No Yes No Good India
Hermann et al.45 1994 23 Propanolol No Yes No Good Austria
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lugol’s iodine in 17 thyrotoxic pa-tients undergoing subtotal thyroid-ectomy. All patients were clinically euthyroid by the time of surgery with no episodes of thyroid storm or exag-geration of the thyrotoxic state post-operatively. Similarly, Gerst in 198626 studied 12 patients prepared with either nadolol or atenolol without iodine. No intolerance or side effects to these medications were noted, and surgery was performed without complication. While the use of these long-acting beta-blockers is less studied than propranolol, existing evidence demonstrates their safety 
and efficacy in the preparation of the hyperthyroid patient for surgery.Esmolol is a very short-acting cardioselective beta-blocker that is given as a continuous intravenous infusion52. It is used primarily in the intensive care setting to treat severe and uncontrolled thyrotoxicosis, and also to control haemodynamics intra-operatively1. Compared with other beta-blockers, this agent has a faster onset and offset of action and is much easier to titrate due to its short half-life. This is advantageous in controlling severe thyrotoxicosis or storm, which are dynamic clinical situations1.
ConclusionIn circumstances where the use of ATDs is not possible in the preop-erative management of patient pre-senting for thyroid or non-thyroid surgery, the use of beta-blockers has been shown to be safe and effec-tive. However, to increase safety, we recommend the use of iodine with or without corticosteroids up to the day of surgery in the rapid preop-erative preparation of the severely thyrotoxic patient. This should not be continued for longer than 10 days. The choice of beta-blocker is clinician-dependent and should be titrated to ideally achieve a heart rate of <90 beats per minute and the ab-sence of symptomatic thyrotoxicosis prior to proceeding to surgery. If this 
Clinical evidence for specific beta-
blockersPropranolol is the most commonly used beta-blocker to treat thyrotoxi-cosis and has been the mainstay beta-blocker therapy to prepare  thyrotoxic patients for surgery21,22,32–40,42,44,45. An advantage of propranolol com-pared to other beta-blockers is that it blocks peripheral conversion of T4 to T3 at high doses. Intravenous propranolol can also be given in the event oral intake is limited post-op-eratively39. A disadvantage is its short half-life requiring high doses and fre-quent administration of up to four times daily to maintain therapeutic plasma levels. This can limit medi-cation compliance and increases the risk of perioperative thyroid storm or hyperthyroid symptoms if doses are missed or inadequate doses are prescribed10. It also has a wide inter-individual variation range40. Being a non-selective beta-blocker, it is con-traindicated in patients with revers-ible obstructive airways disease4.
Difficulties surrounding the use of propranolol led to a number of stud-ies of other beta-blockers, in par-ticular, more cardioselective agents such as metoprolol4. In a double-blind crossover trial by Murchison in 1979,51 each patient received 4 weeks of treatment with proprano-lol and 4 weeks with metoprolol. All showed improvement in clinical symptoms and signs. These results suggest that metoprolol is as effec-tive as propranolol. Furthermore, there is also a stronger association between plasma metoprolol levels 
and clinical efficacy than with pro-
pranolol. These findings are support-ed by Adlerberth 198743 and Vickers in 1990.44 Metoprolol also offers a simpler twice-daily dosing regimen and can be given intravenously when oral administration is limited.Nadolol and atenolol, long-acting beta-blockers, have also been sug-gested as possible alternatives to propranolol26,41. Peden in 198241 re-ported the use of daily nadolol and 
being adequately assessed prior to the commencement of surgery. This is important as there is large indi-vidual variability in response to pro-pranolol40,41,51. Therefore, targets of heart rates <90 beats per minute and absence of symptomatic thyrotoxi-cosis should be used as end points prior to proceeding to surgery.A biochemically euthyroid state is generally considered mandatory pri-or to surgery because of the concern that surgical manipulation of the hy-peractive tissue may precipitate the release of thyroid hormone into the circulation giving rise to a thyroid storm44. Hermann et al. in 1994 re-ported a study of 23 patients with 
severe hyperthyroidism (defined as free T3 or T4 levels at least 300% the maximum normal value) prepared with propranolol alone44. Hormone levels were measured periopera-tively—including from the middle thyroid vein before and after surgi-cal manipulation of the gland, and from the cubital vein after removal of the thyroid lobes. There were no episodes of thyroid storm, and levels of free T4 and T3 were not shown to change with the manipulation of the 
gland. These findings raise the possi-bility that biochemical euthyroidism may not be an absolute prerequisite for thyroidectomy.Use of beta-blockers is also  associated with reduced thyroid gland vascularity, allowing for safe mobilization and resection of the gland by the surgeon. This minimiz-es the risk of excessive blood loss and damage to nerves or parathy-roid glands18,40–43. On the contrary, studies by Lennquist in 198542 and Adlerberth in 198743 reported no dif-ference in the consistency and vas-cularity of thyroids prepared with beta-blockers compared with those prepared with ATD. Importantly, 
they also documented no significant difference in post-operative compli-cations of haemorrhage, hypocal-caemia or recurrent laryngeal nerve injury between the two groups.
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is not possible, then patients should be managed in an intensive care set-ting utilizing an esmolol infusion. Post-operatively, patients should be managed in a high-dependency care setting to provide close supervision 
during the first 24 hours. Beta-block-er therapy should also be continued for 5–7 days with its dose titrated to the patient’s heart rate.
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